SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Silverman, L. B. Articles by Sallan, S. E. Search for Related Content PubMed PubMed Citation Articles by Silverman, L. B. Articles by Sallan, S. E. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 March 2001, Vol. 97, No. 5, pp. 1211-1218 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01 Lewis B. Silverman, Richard D. Gelber, Virginia Kimball Dalton, Barbara L. Asselin, Ronald D. Barr, Luis A. Clavell, Craig A. Hurwitz, Albert Moghrabi, Yvan Samson, Marshall A. Schorin, Steven Arkin, Lieven Declerck, Harvey J. Cohen, and Stephen E. Sallan From the Departments of Pediatric Oncology and Biostatistical Science, Dana-Farber Cancer Institute (DFCI); the Division of Hematology/Oncology, Children's Hospital; the Department of Pediatrics, Harvard Medical School, Boston, MA; the Department of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY; the Department of Pediatrics, McMaster University Medical Center, Hamilton, Ontario, Canada; the San Jorge Children's Hospital, San Juan, Puerto Rico; the Maine Children's Cancer Program, The Barbara Bush Children's Hospital at Maine Medical Center, Portland, ME; the Hospital Saint Justine, Montreal, and the Le Centre Hospitalier de L'Universite, Laval, Quebec, Canada; the Department of Pediatrics, Oschsner Institutions, New Orleans, LA; the Schneider Children's Hospital, New Hyde Park, NY; and the Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA. The Dana-Farber Cancer Institute (DFCI) acute lymphoblastic leukemia (ALL) Consortium Protocol 91-01 was designed to improve the outcome of children with newly diagnosed ALL while minimizing toxicity. Compared with prior protocols, post-remission therapy was intensified by substituting dexamethasone for prednisone and prolonging the asparaginase intensification from 20 to 30 weeks. Between 1991 and 1995, 377 patients (age, 0-18 years) were enrolled; 137 patients were considered standard risk (SR), and 240 patients were high risk (HR). Following a 5.0-year median follow-up, the estimated 5-year event-free survival (EFS) ± SE for all patients was 83% ± 2%, which is superior to prior DFCI ALL Consortium protocols conducted between 1981 and 1991 (P = .03). There was no significant difference in 5-year EFS based upon risk group (87% ± 3% for SR and 81% ± 3% for HR, P = .24). Age at diagnosis was a statistically significant prognostic factor (P = .03), with inferior outcomes observed in infants and children 9 years or older. Patients who tolerated 25 or fewer weeks of asparaginase had a significantly worse outcome than those who received at least 26 weeks of asparaginase (P < .01, both univariate and multivariate). Older children (at least 9 years of age) were significantly more likely to have tolerated 25 or fewer weeks of asparaginase (P < .01). Treatment on Protocol 91-01 significantly improved the outcome of children with ALL, perhaps due to the prolonged asparaginase intensification and/or the use of dexamethasone. The inferior outcome of older children may be due, in part, to increased intolerance of intensive therapy. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. French, W. Yang, C. Cheng, S. C. Raimondi, C. G. Mullighan, J. R. Downing, W. E. Evans, C.-H. Pui, and M. V. Relling Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia Blood, May 7, 2009; 113(19): 4512 - 4520. [Abstract] [Full Text] [PDF] R. Pieters, I. Appel, H.-J. Kuehnel, I. Tetzlaff-Fohr, U. Pichlmeier, I. van der Vaart, E. Visser, and R. Stigter Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial Blood, December 15, 2008; 112(13): 4832 - 4838. [Abstract] [Full Text] [PDF] O. Teuffel, M. Stanulla, G. Cario, W. D. Ludwig, S. Rottgers, B. W. Schafer, M. Zimmermann, M. Schrappe, and F. K. Niggli Anemia and survival in childhood acute lymphoblastic leukemia Haematologica, November 1, 2008; 93(11): 1652 - 1657. [Abstract] [Full Text] [PDF] A. Usvasalo, R. Raty, S. Knuutila, K. Vettenranta, A. Harila-Saari, E. Jantunen, M. Kauppila, P. Koistinen, K. Parto, P. Riikonen, et al. Acute lymphoblastic leukemia in adolescents and young adults in Finland Haematologica, August 1, 2008; 93(8): 1161 - 1168. [Abstract] [Full Text] [PDF] S. Dulucq, G. St-Onge, V. Gagne, M. Ansari, D. Sinnett, D. Labuda, A. Moghrabi, and M. Krajinovic DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL Blood, April 1, 2008; 111(7): 3692 - 3700. [Abstract] [Full Text] [PDF] C. Oudot, M.-F. Auclerc, V. Levy, R. Porcher, C. Piguet, Y. Perel, V. Gandemer, M. Debre, C. Vermylen, B. Pautard, et al. Prognostic Factors for Leukemic Induction Failure in Children With Acute Lymphoblastic Leukemia and Outcome After Salvage Therapy: The FRALLE 93 Study J. Clin. Oncol., March 20, 2008; 26(9): 1496 - 1503. [Abstract] [Full Text] [PDF] A. H. Goldstone, S. M. Richards, H. M. Lazarus, M. S. Tallman, G. Buck, A. K. Fielding, A. K. Burnett, R. Chopra, P. H. Wiernik, L. Foroni, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) Blood, February 15, 2008; 111(4): 1827 - 1833. [Abstract] [Full Text] [PDF] N. L. Seibel Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents: Peaks and Pitfalls Hematology, January 1, 2008; 2008(1): 374 - 380. [Abstract] [Full Text] [PDF] D. P. Waber, J. Turek, L. Catania, K. Stevenson, P. Robaey, I. Romero, H. Adams, C. Alyman, C. Jandet-Brunet, D. S. Neuberg, et al. Neuropsychological Outcomes From a Randomized Trial of Triple Intrathecal Chemotherapy Compared With 18 Gy Cranial Radiation As CNS Treatment in Acute Lymphoblastic Leukemia: Findings From Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 J. Clin. Oncol., November 1, 2007; 25(31): 4914 - 4921. [Abstract] [Full Text] [PDF] J. M. Rowe and A. H. Goldstone How I treat acute lymphocytic leukemia in adults Blood, October 1, 2007; 110(7): 2268 - 2275. [Abstract] [Full Text] [PDF] J. Zhou, M. A Goldwasser, A. Li, S. E. Dahlberg, D. Neuberg, H. Wang, V. Dalton, K. D McBride, S. E. Sallan, L. B Silverman, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01 Blood, September 1, 2007; 110(5): 1607 - 1611. [Abstract] [Full Text] [PDF] A. R. Chauvenet, P. L. Martin, M. Devidas, S. B. Linda, B. A. Bell, J. Kurtzberg, J. Pullen, M. J. Pettenati, A. J. Carroll, J. J. Shuster, et al. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201 Blood, August 15, 2007; 110(4): 1105 - 1111. [Abstract] [Full Text] [PDF] D. A. Williams A New Mechanism of Leukemia Drug Resistance? N. Engl. J. Med., July 5, 2007; 357(1): 77 - 78. [Full Text] [PDF] S. Kishi, C. Cheng, D. French, D. Pei, S. Das, E. H. Cook, N. Hijiya, C. Rizzari, G. L. Rosner, T. Frudakis, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity Blood, May 15, 2007; 109(10): 4151 - 4157. [Abstract] [Full Text] [PDF] I. Paz-Priel, L. Long, L. J. Helman, C. L. Mackall, and A. S. Wayne Thromboembolic Events in Children and Young Adults With Pediatric Sarcoma J. Clin. Oncol., April 20, 2007; 25(12): 1519 - 1524. [Abstract] [Full Text] [PDF] D. Douer, H. Yampolsky, L. J. Cohen, K. Watkins, A. M. Levine, A. P. Periclou, and V. I. Avramis Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia Blood, April 1, 2007; 109(7): 2744 - 2750. [Abstract] [Full Text] [PDF] N. Hijiya, M. M. Hudson, S. Lensing, M. Zacher, M. Onciu, F. G. Behm, B. I. Razzouk, R. C. Ribeiro, J. E. Rubnitz, J. T. Sandlund, et al. Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic Leukemia JAMA, March 21, 2007; 297(11): 1207 - 1215. [Abstract] [Full Text] [PDF] E. Barry, D. J. DeAngelo, D. Neuberg, K. Stevenson, M. L. Loh, B. L. Asselin, R. D. Barr, L. A. Clavell, C. A. Hurwitz, A. Moghrabi, et al. Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols J. Clin. Oncol., March 1, 2007; 25(7): 813 - 819. [Abstract] [Full Text] [PDF] A. Moghrabi, D. E. Levy, B. Asselin, R. Barr, L. Clavell, C. Hurwitz, Y. Samson, M. Schorin, V. K. Dalton, S. E. Lipshultz, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia Blood, February 1, 2007; 109(3): 896 - 904. [Abstract] [Full Text] [PDF] J.-M. Ribera, J.-J. Ortega, A. Oriol, P. Bastida, C. Calvo, J.-M. Perez-Hurtado, M.-E. Gonzalez-Valentin, V. Martin-Reina, A. Molines, F. Ortega-Rivas, et al. Comparison of Intensive Chemotherapy, Allogeneic, or Autologous Stem-Cell Transplantation As Postremission Treatment for Children With Very High Risk Acute Lymphoblastic Leukemia: PETHEMA ALL-93 Trial J. Clin. Oncol., January 1, 2007; 25(1): 16 - 24. [Abstract] [Full Text] [PDF] U. M. Saarinen-Pihkala, C. Heilmann, J. Winiarski, A. Glomstein, J. Abrahamsson, J. Arvidson, A. N. Bekassy, E. Forestier, G. Jonmundsson, H. Schroeder, et al. Pathways Through Relapses and Deaths of Children With Acute Lymphoblastic Leukemia: Role of Allogeneic Stem-Cell Transplantation in Nordic Data J. Clin. Oncol., December 20, 2006; 24(36): 5750 - 5762. [Abstract] [Full Text] [PDF] J. M. Storring, J. Brandwein, V. Gupta, A. C. Schuh, A. Schimmer, K. Yee, R. A. Wells, J. H. Lipton, H. A. Messner, W. Xu, et al. Treatment of Adult Acute Lymphoblastic Leukemia (ALL) with a Modified DFCI Pediatric Regimen - The Princess Margaret Experience. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 1875 - 1875. [Abstract] [PDF] V. Caruso, L. Iacoviello, A. Di Castelnuovo, S. Storti, G. Mariani, G. de Gaetano, and M. B. Donati Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients Blood, October 1, 2006; 108(7): 2216 - 2222. [Abstract] [Full Text] [PDF] M. Eapen, E. Raetz, M.-J. Zhang, C. Muehlenbein, M. Devidas, T. Abshire, A. Billett, A. Homans, B. Camitta, W. L. Carroll, et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research Blood, June 15, 2006; 107(12): 4961 - 4967. [Abstract] [Full Text] [PDF] M. L. Loh, M. A. Goldwasser, L. B. Silverman, W.-M. Poon, S. Vattikuti, A. Cardoso, D. S. Neuberg, K. M. Shannon, S. E. Sallan, and D. G. Gilliland Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01 Blood, June 1, 2006; 107(11): 4508 - 4513. [Abstract] [Full Text] [PDF] J. Feusner Bcl-rambo: a maverick of apoptotic genes Blood, January 15, 2006; 107(2): 421 - 421. [Full Text] [PDF] J. O'Neil, J. Calvo, K. McKenna, V. Krishnamoorthy, J. C. Aster, C. H. Bassing, F. W. Alt, M. Kelliher, and A. T. Look Activating Notch1 mutations in mouse models of T-ALL Blood, January 15, 2006; 107(2): 781 - 785. [Abstract] [Full Text] [PDF] J. M. Rowe, G. Buck, A. K. Burnett, R. Chopra, P. H. Wiernik, S. M. Richards, H. M. Lazarus, I. M. Franklin, M. R. Litzow, N. Ciobanu, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993 Blood, December 1, 2005; 106(12): 3760 - 3767. [Abstract] [Full Text] [PDF] C.-H. Pui, D. Pei, J. T. Sandlund, D. Campana, R. C. Ribeiro, B. I. Razzouk, J. E. Rubnitz, S. C. Howard, N. Hijiya, S. Jeha, et al. Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia J. Clin. Oncol., November 1, 2005; 23(31): 7936 - 7941. [Abstract] [Full Text] [PDF] H. G. Einsiedel, A. von Stackelberg, R. Hartmann, R. Fengler, M. Schrappe, G. Janka-Schaub, G. Mann, K. Hahlen, U. Gobel, T. Klingebiel, et al. Long-Term Outcome in Children With Relapsed ALL by Risk-Stratified Salvage Therapy: Results of Trial Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-Munster Group 87 J. Clin. Oncol., November 1, 2005; 23(31): 7942 - 7950. [Abstract] [Full Text] [PDF] S. Igarashi, A. Manabe, A. Ohara, M. Kumagai, T. Saito, Y. Okimoto, T. Kamijo, K. Isoyama, M. Kajiwara, M. Sotomatsu, et al. No Advantage of Dexamethasone Over Prednisolone for the Outcome of Standard- and Intermediate-Risk Childhood Acute Lymphoblastic Leukemia in the Tokyo Children's Cancer Study Group L95-14 Protocol J. Clin. Oncol., September 20, 2005; 23(27): 6489 - 6498. [Abstract] [Full Text] [PDF] G. Zaza, M. Cheok, W. Yang, J. C. Panetta, C.-H. Pui, M. V. Relling, and W. E. Evans Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment Blood, September 1, 2005; 106(5): 1778 - 1785. [Abstract] [Full Text] [PDF] M. J Wright, V. Galea, and R. D Barr Proficiency of Balance in Children and Youth Who Have Had Acute Lymphoblastic Leukemia Physical Therapy, August 1, 2005; 85(8): 782 - 790. [Abstract] [Full Text] [PDF] J. C. C. Rocha, C. Cheng, W. Liu, S. Kishi, S. Das, E. H. Cook, J. T. Sandlund, J. Rubnitz, R. Ribeiro, D. Campana, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia Blood, June 15, 2005; 105(12): 4752 - 4758. [Abstract] [Full Text] [PDF] D. J. DeAngelo The Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia Hematology, January 1, 2005; 2005(1): 123 - 130. [Abstract] [Full Text] [PDF] C.-H. Pui, J. T. Sandlund, D. Pei, D. Campana, G. K. Rivera, R. C. Ribeiro, J. E. Rubnitz, B. I. Razzouk, S. C. Howard, M. M. Hudson, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital Blood, November 1, 2004; 104(9): 2690 - 2696. [Abstract] [Full Text] [PDF] S. E. Lipshultz, N. Rifai, V. M. Dalton, D. E. Levy, L. B. Silverman, S. R. Lipsitz, S. D. Colan, B. L. Asselin, R. D. Barr, L. A. Clavell, et al. The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia N. Engl. J. Med., July 8, 2004; 351(2): 145 - 153. [Abstract] [Full Text] [PDF] D. P. Waber, L. B. Silverman, L. Catania, W. Mautz, M. Rue, R. D. Gelber, D. E. Levy, M. A. Goldwasser, H. Adams, A. Dufresne, et al. Outcomes of a Randomized Trial of Hyperfractionated Cranial Radiation Therapy for Treatment of High-Risk Acute Lymphoblastic Leukemia: Therapeutic Efficacy and Neurotoxicity J. Clin. Oncol., July 1, 2004; 22(13): 2701 - 2707. [Abstract] [Full Text] [PDF] S. C. Howard, M. Pedrosa, M. Lins, A. Pedrosa, C.-H. Pui, R. C. Ribeiro, and F. Pedrosa Establishment of a Pediatric Oncology Program and Outcomes of Childhood Acute Lymphoblastic Leukemia in a Resource-Poor Area JAMA, May 26, 2004; 291(20): 2471 - 2475. [Abstract] [Full Text] [PDF] C.-H. Pui, M. V. Relling, and J. R. Downing Acute Lymphoblastic Leukemia N. Engl. J. Med., April 8, 2004; 350(15): 1535 - 1548. [Full Text] [PDF] T. M. Holling, E. Schooten, A. W. Langerak, and P. J. van den Elsen Regulation of MHC class II expression in human T-cell malignancies Blood, February 15, 2004; 103(4): 1438 - 1444. [Abstract] [Full Text] [PDF] C.-H. Pui, M. Schrappe, R. C. Ribeiro, and C. M. Niemeyer Childhood and Adolescent Lymphoid and Myeloid Leukemia Hematology, January 1, 2004; 2004(1): 118 - 145. [Abstract] [Full Text] [PDF] M. E. Ross, X. Zhou, G. Song, S. A. Shurtleff, K. Girtman, W. K. Williams, H.-C. Liu, R. Mahfouz, S. C. Raimondi, N. Lenny, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling Blood, October 15, 2003; 102(8): 2951 - 2959. [Abstract] [Full Text] [PDF] J. M. Goldberg, L. B. Silverman, D. E. Levy, V. K. Dalton, R. D. Gelber, L. Lehmann, H. J. Cohen, S. E. Sallan, and B. L. Asselin Childhood T-Cell Acute Lymphoblastic Leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Experience J. Clin. Oncol., October 1, 2003; 21(19): 3616 - 3622. [Abstract] [Full Text] [PDF] S. Tsutsumi, T. Taketani, K. Nishimura, X. Ge, T. Taki, K. Sugita, E. Ishii, R. Hanada, M. Ohki, H. Aburatani, et al. Two Distinct Gene Expression Signatures in Pediatric Acute Lymphoblastic Leukemia with MLL Rearrangements Cancer Res., August 15, 2003; 63(16): 4882 - 4887. [Abstract] [Full Text] [PDF] C.-H. Pui, C. Cheng, W. Leung, S. N. Rai, G. K. Rivera, J. T. Sandlund, R. C. Ribeiro, M. V. Relling, L. E. Kun, W. E. Evans, et al. Extended Follow-up of Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia N. Engl. J. Med., August 14, 2003; 349(7): 640 - 649. [Abstract] [Full Text] [PDF] V. K. Dalton, M. Rue, L. B. Silverman, R. D. Gelber, B. L. Asselin, R. D. Barr, L. A. Clavell, C. A. Hurwitz, A. Moghrabi, Y. Samson, et al. Height and Weight in Children Treated for Acute Lymphoblastic Leukemia: Relationship to CNS Treatment J. Clin. Oncol., August 1, 2003; 21(15): 2953 - 2960. [Abstract] [Full Text] [PDF] B. C. Bostrom, M. R. Sensel, H. N. Sather, P. S. Gaynon, M. K. La, K. Johnston, G. R. Erdmann, S. Gold, N. A. Heerema, R. J. Hutchinson, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group Blood, May 15, 2003; 101(10): 3809 - 3817. [Abstract] [Full Text] [PDF] M. Clarke, P. Gaynon, I. Hann, G. Harrison, G. Masera, R. Peto, and S. Richards CNS-Directed Therapy for Childhood Acute Lymphoblastic Leukemia: Childhood ALL Collaborative Group Overview of 43 Randomized Trials J. Clin. Oncol., May 1, 2003; 21(9): 1798 - 1809. [Abstract] [Full Text] [PDF] N. Boissel, M.-F. Auclerc, V. Lheritier, Y. Perel, X. Thomas, T. Leblanc, P. Rousselot, J.-M. Cayuela, J. Gabert, N. Fegueux, et al. Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials J. Clin. Oncol., March 1, 2003; 21(5): 774 - 780. [Abstract] [Full Text] [PDF] C.-H. Pui Toward Optimal Central Nervous System-Directed Treatment in Childhood Acute Lymphoblastic Leukemia J. Clin. Oncol., January 15, 2003; 21(2): 179 - 181. [Full Text] [PDF] R. M. Stone The Difficult Problem of Acute Myeloid Leukemia in the Older Adult CA Cancer J Clin, November 1, 2002; 52(6): 363 - 371. [Abstract] [Full Text] [PDF] P. Ballerini, A. Blaise, M. Busson-Le Coniat, X. Y. Su, J. Zucman-Rossi, M. Adam, J. van den Akker, C. Perot, B. Pellegrino, J. Landman-Parker, et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis Blood, July 18, 2002; 100(3): 991 - 997. [Abstract] [Full Text] [PDF] S. E. Lipshultz, A. L. Giantris, S. R. Lipsitz, V. K. Dalton, B. L. Asselin, R. D. Barr, L. A. Clavell, C. A. Hurwitz, A. Moghrabi, Y. Samson, et al. Doxorubicin Administration by Continuous Infusion Is Not Cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol J. Clin. Oncol., March 15, 2002; 20(6): 1677 - 1682. [Abstract] [Full Text] [PDF] B. J. Lange, B. C. Bostrom, J. M. Cherlow, M. G. Sensel, M. K. L. La, W. Rackoff, N. A. Heerema, R. S. Wimmer, M. E. Trigg, and H. N. Sather Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group Blood, February 1, 2002; 99(3): 825 - 833. [Abstract] [Full Text] [PDF] J. M. LeClerc, A. L. Billett, R. D. Gelber, V. Dalton, N. Tarbell, J. M. Lipton, R. Barr, L. A. Clavell, B. Asselin, C. Hurwitz, et al. Treatment of Childhood Acute Lymphoblastic Leukemia: Results of Dana-Farber ALL Consortium Protocol 87-01 J. Clin. Oncol., January 1, 2002; 20(1): 237 - 246. [Abstract] [Full Text] [PDF] D. Hoelzer, N. Gokbuget, O. Ottmann, C.-H. Pui, M. V. Relling, F. R. Appelbaum, J. J.M. van Dongen, and T. Szczepanski Acute Lymphoblastic Leukemia Hematology, January 1, 2002; 2002(1): 162 - 192. [Abstract] [Full Text] [PDF] A. J. Strauss, J. T. Su, V. M. K. Dalton, R. D. Gelber, S. E. Sallan, and L. B. Silverman Bony Morbidity in Children Treated for Acute Lymphoblastic Leukemia J. Clin. Oncol., June 15, 2001; 19(12): 3066 - 3072. [Abstract] [Full Text] [PDF]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020